论文部分内容阅读
目的观察吡嗪酰胺凝胶体外抗结核作用和支气管介入的安全性。方法手工法、仪器法分别测定吡嗪酰胺单体、吡嗪酰胺凝胶的最小抑菌浓度(MIC)和最小杀菌浓度(MBC)及家兔经支气管介入的安全性试验。结果吡嗪酰胺凝胶对人型结核分枝杆菌标准株、牛型结核分枝杆菌、草分枝杆菌MIC值分别为1.0、1.0、10mg/L,MBC值分别为10、10、40mg/L;吡嗪酰胺凝胶与吡嗪酰胺单体MIC、MBC值无显著性差异;动物安全性试验阴性。结论吡嗪酰胺凝胶具有与吡嗪酰胺单体相同的抗结核菌药效,卡波姆基质不影响吡嗪酰胺的抗菌活性;卡波姆基质吡嗪酰胺凝胶应用安全。
Objective To observe the antitubercular effect of pyrazinamide gel in vitro and the safety of bronchial intervention. Methods The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of pyrazinamide monomer and pyrazinamide gel and the safety test of bronchial intervention in rabbits were respectively determined by manual method and instrumental method. Results The MIC value of pyrazinamide gel for standard strain of Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium phlei were 1.0, 1.0 and 10 mg / L, MBC values were 10, 10 and 40 mg / L ; Pyrazinamide gel and pyrazinamide monomer MIC, MBC value no significant difference; animal safety test was negative. Conclusions Pyrazinamide gel has the same anti-TB efficacy as pyrazinamide monomer, while carbomer matrix does not affect the antimicrobial activity of pyrazinamide. Carbamate-based pyrazinamide gel is safe to use.